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abstract: First discovered by Friedenstein in 1976, mesenchymal stem cells (MSCs) are adult stem cells found 
throughout the body that share a fixed set of characteristics. Discovered initially in the bone marrow, this cell 
source is considered the gold standard for clinical research, although various other sources—including adipose 
tissue, dental pulp, mobilised peripheral blood and birth-derived tissues—have since been identified. Although 
similar, MSCs derived from different sources possess distinct characteristics, advantages and disadvantages, 
including their differentiation potential and proliferation capacity, which influence their applicability. Hence, 
they may be used for specific clinical applications in the fields of regenerative medicine and tissue engineering. 
This review article summarises current knowledge regarding the various sources, characteristics and therapeutic 
applications of MSCs.
Keywords: Mesenchymal Stem Cells; Adult Stem Cells; Regenerative Medicine; Cell Differentiation; Tissue 
Engineering.
امللخ�ص: اخلاليا اجلذعية الو�شيطة التي مت اكت�شافها لأول مرة بوا�شطة فريدن�شتاين يف عام 1976 هي اخلاليا اجلذعية البالغة املوجودة 
يف جميع اأنحاء اجل�شم والتي ت�شرتك يف جمموعة ثابتة من اخل�شائ�ص. مت اكت�شاف هذه اخلالايا يف البداية يف نخاع العظام، ويعترب 
هذا امل�شدر اخللوي هو املعيار الذهبي للبحوث ال�رسيرية، على الرغم من اأنه مت منذ ذلك احلني حتديد م�شادر اأخرى متنوعة-مبا يف ذلك 
الأن�شجة الدهنية، ولب الأ�شنان، وخاليا الدم الطرفية املحركة والأن�شجة امل�شتقة من م�شيمة الولدة. وعلى الرغم من كونها مت�شابهة، 
اإمكاناتها يف  ذلك  امل�شادر خمتلفة متتلك خ�شائ�ص مميزة ومزايا وعيوب، مبا يف  تلك  امل�شتمدة من  الو�شيطة  فاإن اخلاليا اجلذعية 
التمايز وقدرتها على النت�شار، والتي توؤثر على قابليتها للتطبيق. ومن ثم، ميكن ا�شتخدامها يف تطبيقات �رسيرية حمددة يف جمالت 
الطب التجديدي وهند�شة الأن�شجة. تلخ�ص هذه املقالة املعرفة احلالية فيما يتعلق مبختلف امل�شادر واخل�شائ�ص والتطبيقات العالجية 
للخاليا اجلذعية الو�شيطة.
الكلمات املفتاحية: اخلاليا اجلذعية الو�شيطة؛ اخلاليا اجلذعية للبالغني؛ الطب التجديدي؛ متايز اخلاليا؛ هند�شة الن�شجة.
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Stem cells can be distinguished based on their differentiation potential and source within the human body. Embryonic stem cells are toti-
potent, because they can form both embryonic and extra- 
embryonic structures.1 Furthermore, embryonic stem 
cells can proliferate indefinitely under specific culture 
conditions and retain the ability to differentiate into cell 
types of the three embryonic germ layers.1,2 In contrast, 
adult stem cells are undifferentiated multipotent stem 
cells obtained from adult individuals and differentiate 
into the cell types that constitute their respective source 
tissues; accordingly, cells originating from neuronal 
tissue can differentiate into neurons, oligodendrocytes 
or astrocytes. This characteristic plasticity is an attribute 
of mesenchymal stem cells (MSCs), which are unspec-
ialised cells with the ability to self-renew.3,4 
Human MSCs are plastic-adherent cells that differ- 
entiate into cells that originate from the ectoderm and 
endoderm.3–5 Moreover, they can abandon their unspec- 
ialised or undifferentiated states and transform into 
other mesenchymal lineages. Thus, they can regenerate 
bone, cartilage and fat and even become endothelial 
cells, muscle cells or neurons under physiological and 
experimental conditions.3,4 While evidence suggests that 
MSCs are present in almost all human tissues, they 
were first isolated from mononuclear cells derived from 
bone marrow (BM).3,6
As MSCs are responsible for tissue repair, growth, 
wound healing and cell substitution resulting from 
physiological or pathological causes, they have various 
therapeutic applications such as in the treatment of 
central nervous system afflictions like spinal cord lesions.4
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Moreover, because of their differentiation ability, MSCs 
have become the de facto model for regenerative medic-
ine research.3,5,6 In the field of regenerative medicine, 
MSCs have several advantages over other types of stem 
cells. For example, from an ethical standpoint, the contr- 
oversy that surrounds the procurement of embryonic 
stem cells is virtually nonexistent in the case of induced 
pluripotent stem cells or MSCs, although teratogenicity 
limits the widespread use of the former cell type.3,4,6
The objective of the current review was to highlight 
the available information regarding MSC sources and 
their potential applications in the treatment of a variety 
of diseases. However, in order to present a comprehensive 
overview of the possible clinical applications of MSCs, it is 
first necessary to understand their unique characteristics, 
including their differentiation potential, activity and 
therapeutic effects in various human systems and 
tissues.
Differentiation Potential
MSCs can differentiate into different cell types, although 
they require an array of differentiation factors. In an 
in vitro environment, the specific growth medium allows 
them to reach their osteogenic, chondrogenic or adipo- 
genic potential.7,8 However, due to the use of different 
isolation and culture techniques, there are conflicting 
data regarding the specific characteristics used to 
define MSCs. Since these cells can be isolated from 
almost any tissue, it has been proposed that MSCs 
from various sources might not be similar enough 
to be grouped together under a single classification.6 
However, this issue has been resolved following 
the establishment of universally accepted laboratory 
criteria allowing for the identification of common MSC 
characteristics.8 
According to the International Society for Cellular 
Therapy, multipotent MSCs must meet the following 
three criteria: plastic adherence to culture flasks; expres- 
sion of cluster of differentiation (CD)105, CD73 and 
CD90 and lack of expression of CD45, CD34, CD14/ 
CD11b, CD79α/CD19 and human leukocyte antigen 
(HLA) class II by ≥95% and ≤2% of the cell population, 
respectively; and the ability to differentiate into osteo-
blasts, chondroblasts or adipocytes.8 In addition, under 
specific culture conditions, MSCs can differentiate into 
non-mesodermal lineages such as hepatocytes, neurons, 
pancreatic cells, cardiac muscle cells or astrocytes.9 
Sources and Clinical 
Applications
Stem cells can be isolated from various sources in the 
human body, the selection of which should ideally be 
based on their logistical, practical and in vitro charact-
eristics. Currently, the main sources of MSCs are BM 
and adipose tissue (AT).6 Although MSCs can hypo-
thetically be obtained from almost any tissue within the 
human body, there are practical limitations concerning 
the difficulty and invasiveness of the procurement 
process and various donor characteristics. To select an 
adequate cell source, the practitioner must consider the 
difficulty of procuring the samples and the potential 
adverse effects of harvesting the cells on the donor. 
Obtaining BM-MSCs, for example, can result in pain, 
bleeding or infection, thus making harvesting MSCs 
from this source more problematic than harvesting 
cells from peripheral blood or surgical remnants such 
as AT or birth-derived tissues.9 Table 1 describes 
current sources of MSCs along with their character- 
istics, advantages, disadvantages and clinical applic-
ations.7,9–30
bone marrow
Initially discovered in 1976 by Friedenstein, BM-MSCs 
were first described as undifferentiated MSCs in 1987.31,32
Subsequently, BM became the main source of multi-
potent stem cells. However, their procurement requires 
a highly invasive and painful procedure involving heavy 
use of anaesthesia; moreover, the cell yield, longevity 
and potential for differentiation diminishes with donor 
age.9 Compared with MSCs derived from other sources, 
BM-MSCs possess a longer duplication period, reach 
senescence earlier and constitute only 0.01–0.001% of 
nucleated marrow cells.9,10 Nevertheless, one advant-
age of BM-MSCs over other cell types is their relatively 
short culture time.11,33
The role of inflammation in the pathogenesis of 
arterial hypertension, particularly in activating the 
sympathetic nervous system, has been recently ident-
ified in a study using a murine model.34 Penn et al. 
observed that BM transplantation from spontaneously 
hypertensive rats into normotensive rats resulted in a 
marked increase in blood pressure; however, treating 
the rats with minocycline, a second-generation semi- 
synthetic tetracycline and microglial activation inhib-
itor with anti-inflammatory effects, reversed the hyper- 
tension.34 The underlying mechanism involves an inc- 
rease in the production of inflammatory cells and 
cytokines which translates into a stronger neuro-
inflammatory response and increased activity of the 
sympathetic nervous system. The association between 
haematopoietic (i.e. BM-derived) stem cells and hyper- 
tension indicates that BM-MSC therapy may have poten- 
tial applications in treating obesity, diabetes mellitus 
(DM) and hypertension.34 
In a clinical context, attempts have been made to 
use BM-MSCs to alleviate heart failure, address cardio-
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myocyte loss to improve heart function and prevent end- 
stage heart failure. Although clinical trials in both human 
and animal models have been promising, a meta-analysis 
of 10 large-scale randomised phase two trials using BM-
derived cells showed negligible benefits after an acute 
myocardial infarction.35–42 In preclinical and clinical 
studies, intravenous, intracoronary or intramyocardial 
routes represent the main options for cell delivery within 
minutes to a few months after a myocardial infarction.37–42 
However, protocol variations impede the accurate inter- 
pretation of preclinical and clinical trial results.41,42 Forest 
et al. compared cellular retention and engraftment with 
in vivo imaging in a porcine model using different admin- 
istration routes.40 Following an intracoronary injection, 
the safest and easiest delivery method, 34.8 ± 9.9% 
of cells were detected in the heart after one hour; 
this proportion declined precipitously to 6.0 ± 1.7% 
after 24 hours.40 Inconsistent results regarding the 
benefits of BM cell therapy in cardiac function may 
be due to variability in cell survival, engraftment and 
differentiation.39 
Currently, several ongoing clinical trials are being 
conducted to establish the usefulness of BM-MSCs, 
especially in the context of ischaemic heart failure. 
Diastolic left ventricular (LV) dysfunction represents a 
frequent complication after acute myocardial infarction 
and a major risk factor for the development of heart 
failure, independent of preserved LV ejection fraction.41 
Schaefer et al. conducted a follow-up study of 60 
patients with ST-segment elevation acute myocardial 
infarction treated by BM-MSC transfer.42 The time trend 
of the diastolic function and the E/A ratio remained 
unchanged in the experimental BM-MSC group relative 
to the control group, in which the E/A ratio decreased 
over the course of 60 months. However, the duration 
of the improvement noted in the experimental group 
did not exceed five years.42 Importantly, no arrhyth- 
mogenic or tumourigenic effects have been observed in 
the treatment of myocardial infarction with BM-MSCs.7 
In allogeneic (i.e. haematopoietic) stem cell transpl- 
antation, graft-versus-host disease (GVHD)—in which 
immunocompetent donor cells recognise and attack 
tissues in an immunocompromised host—is a significant 
cause of morbidity and mortality.11 Traditional manage- 
ment entails immunosuppression with corticosteroids 
as first-line therapy, a treatment that produces sust-
ained responses in <40–50% of patients with GVHD.43 
However, corticosteroid-refractory patients require 
effective second- and third-line treatment options.44 The 
allogeneic transplantation of BM-MSCs can, when obt- 
ained from major histocompatibility complex-matched 
donors (i.e. a mother or twin), induce immunosuppr-
ession in the recipient and thus be used to treat 
GVHD. This effect was initially evaluated in murine 
models wherein MSCs inhibited naive and memory 
antigen-specific T cells.45 BM-MSCs have also been 
used to treat systemic lupus erythematosus (SLE), 
multiple sclerosis (MS), autoimmune encephalomyelitis, 
asthma, allergic rhinitis and pulmonary fibrosis. Except 
for SLE and MS, these applications have all been tested 
in animal models.7 The efficacy and safety of using 
BM-MSCs in GVDH patients is being tested in on- 
going clinical trials based on growing evidence high-
lighting the key role of BM-MSCs in modulating 
inflammation.46 
In the digestive system, BM-MSCs can improve 
liver cirrhosis and liver failure caused by hepatitis B 
infections, with positive changes according to chronic 
liver disease staging and prognostic scales.47 Other 
important applications of BM-MSCs are in ortho-
paedics. For example, BM aspirates from the iliac crest 
have been used to treat atrophic diaphyseal non-unions, 
leading to callus formation.9,12 Placing BM-MSCs on 
scaffolds has been shown to regenerate meniscus 
tissue in rabbits and BM-MSCs placed on conduits 
or grafts have been used to treat nerve defects, with 
better results than cell-depleted grafts.9 Furthermore, 
BM-MSCs have been transplanted to various injured 
tendon sites, resulting in enhanced tissue repair, esp-
ecially for injuries of the patellar tendon.9 
Another important application of BM-MSCs is 
in the treatment of spinal cord injuries. When mixed 
with minocycline, BM-MSCs have resulted in improved 
spinal cord injuries in a rat model.9 As such, these 
cells may represent a promising approach for neuro-
protection following spinal cord injury. BM-MSCs 
have also been used to treat osteogenesis imperfecta 
in a mouse model, in which BM-MSCs from a disease-
free mouse were infused into an affected mouse.9 This 
treatment promoted the differentiation of migrated 
cells into osteocytes and synthesised standard amounts 
of type I collagen, partially reverting the disease pheno-
type. Other BM-MSC applications include muscular 
dystrophy, physical defects and rotator cuff injuries.9
adipose tissue
The main advantage of using AT as an MSC source 
is convenience, as human subcutaneous AT is usually 
abundant throughout the body and is a byproduct of 
cosmetic and therapeutic liposuction procedures. It is 
estimated that approximately 98–100% of cells obtained 
from AT are viable.5,48 The morphological, phenotypical 
and functional characteristics of AT-MSCs are similar 
to those of BM-MSCs.48 Besides their stability in long-
term cell cultures, AT-MSCs can expand effectively in 
vitro and possess high multilineage differentiation pot- 
ential. The stromal vascular AT fraction produces more 
stromal elements than the mononuclear BM fraction, 
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even though these stromal elements may represent 
other lineages, such as endothelial, haematopoietic and 
pericyclic origins.48–50 Thus, AT represents a more pract- 
ical autologous source of MSCs for tissue engineering 
than BM. However, one limitation of AT-MSCs is that 
certain donor characteristics, such as age, can affect the 
expansion and differentiation of AT-MSCs, particularly 
into osteogenic and chondrogenic lineages, although 
the adipogenic lineage is not affected.48
Besides their ability to differentiate and self-renew, 
AT-MSCs secrete several cytokines and growth factors 
with anti-inflammatory, antiapoptotic and immuno-
modulatory properties. Examples include vascular endo- 
thelial growth factor, hepatocyte growth factor and 
insulin-like growth factor, all of which are involved in 
angiogenesis and tissue repair. These characteristics 
render AT-MSCs prime candidates for treating ischaemic 
diseases.5 Additionally, due to the immunomodulatory 
effects of human AT-MSCs, AT is an excellent source 
of MSCs for allogeneic transplants and, as AT-MSCs 
do not express major histocompatibility complex type 
II antigens, the risk of rejection is minimised.11 AT-
MSCs regulate the function of T cells by promoting 
the induction of suppressor T cells and inhibiting the 
production of cytotoxic T cells, natural killer cells and 
proinflammatory cytokines (including tumour necrosis 
factor-α, interferon-γ and interleukin [IL]-12). Further-
more, these cells secrete soluble factors, such as IL-10, 
transforming growth factor-β and prostaglandin E2, 
making these cells immunosuppressive.5,11
It should be noted that the p53 protein plays a key 
role in the differentiation of human AT-MSCs cells, 
affecting their osteogenic and adipogenic potential 
by suppressing the osterix, runt-related transcription 
factor and peroxisome proliferator-activated receptor 
(PPAR) genes.51 In various malignancies, p53 function 
is limited, thus offering the possibility of using cancer cells 
from mutant MSCs to investigate treatment targets.51,52 
A recent study by Inatani et al. compared the 
differentiation potential of MSCs from normal AT 
and atypical lipomatous tumour/well-differentiated 
liposarcoma (ALT/WDL).49 The osteogenic differen-
tiation potential in ALT/WDL-MSCs was greater than 
that of the normal AT group, although normal AT 
produced more fatty acid droplets during adipogenic 
differentiation than ALT/WDL.49 This type of study 
offers an interesting approach to therapeutics in that 
it postulates using differentiation as a means of treatment. 
This concept has also been explored with the use of 
troglitazone in patients with liposarcoma, defective 
proliferation, apoptosis and differentiation.50 Histological 
tumour changes were observed in a small follow-up 
study of patients with myxoid and pleomorphic liposarc- 
omas; six months after the administration of PPAR-γ 
ligand, troglitazone, the researchers observed microves- 
icular cytoplasmic lipid accumulation and diminished 
proliferation according to Ki-67 expression.50 Although 
imaging indicated that the tumour size increased 
as a result of intracellular lipid accumulation, with a 
corresponding increase in cellular volume, no new 
tumour sites were found. Thus, it may be possible to 
modify the pathophysiology of cancer and reduce the 
proliferation of malignant cells by promoting cellular 
differentiation.50
Additionally, AT-MSCs may be useful for myo-
cardial regeneration. In one trial, AT-MSC application 
resulted in improved cardiac function, elevated per- 
fusion and a reduction in the extension of scar tissue.7 
AT-MSCs have also been used extensively for derma-
tological and cosmetic purposes. These cells promote 
wound healing by enhancing the secretion of type I 
collagen, upregulating the expression of type III collagen 
and fibronectin and downregulating matrix metallopro- 
teinase-1 in fibroblasts.13 They have also been shown to 
accelerate granulation tissue and capillary formation 
and epithelisation in DM-induced tissue damage. More- 
over, AT-MSCs have been used for wrinkle reduction, 
skin whitening (by inhibiting melanin synthesis), as anti- 
oxidants and for the promotion of hair growth.13
Furthermore, AT-MSCs have accelerated skeletal 
muscle regeneration in a rat model.9 Interestingly, AT- 
MSCs express various neuronal and Schwann cell 
markers, such as myelin protein zero, myelin basic pro-
tein and peripheral myelin 22, suggesting that they may 
possess a myelin-generating capacity. These cells have 
also been used to treat nerve defects and neuropathic 
pain in rats with promising results.9 Finally, AT-MSCs 
have been used to treat collagenase-induced tendinitis 
in horses, improving tendon organisation and success-
fully treating rotator cuff injuries.9
dental pulp
Dental pulp (DP)-derived MSCs specialise into odont- 
oblasts, which produce dentin.14 These cells are obtained 
from pulp tissue from the third molar and are extracted 
by an enzymatic digestive process. Overall, DP-MSCs 
are easy to cryopreserve and, similarly to AT-MSCs, 
possess immunomodulatory properties.14 Since DP-
MSCs are derived from the neural crest, they have 
ectomesenchymal origins and both ectodermal and 
mesenchymal lineages. Hence, in addition to different-
iating into osteo/chondroblasts and adipocytes, DP- 
MSCs can also differentiate into neuronal lineages. When 
cultured in a three-dimensional (3D) dentin scaffold, 
DP-MSCs can differentiate into corneal epithelial 
cells, melanocytes and induced pluripotent stem cells, 
rendering them highly useful in regenerative medicine 
research.14,15,53
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The most promising clinical applications for this 
stem cell source involve the correction of metabolic 
diseases and the treatment of liver diseases with high 
mortality rates, such as cirrhosis and hepatocellular 
carcinoma.54,55 Over time, DP-MSCs have become the 
preferred alternative to harvesting stem cells during 
hepatic transplantation.15 DP-MSCs have also been used 
in the field of bone regeneration. When DP-MSCs are 
cultured on hydrogels, they can spontaneously differ- 
entiate into both odontogenic and osteogenic pheno-
types.55,56
A specific type of DP-MSCs, known as periapical 
cyst (PCy)-MSCs, have gained special attention because 
of their extensive proliferative potential, cell surface marker 
profile and ability to differentiate into various cell types, 
such as osteoblasts, adipocytes and neurons.16,17,55,56 
Importantly, these cells are easily collected from 
surgically removed PCys, thus allowing for the reuse of 
biological waste. They have also been used in the field 
of bone regeneration. Due to their neural plasticity, 
these cells represent an interesting option for treating 
neurodegenerative diseases.16
birth-derived tissues
Currently, umbilical cord blood (UCB) is not universally 
accepted as a source of MSCs.57 Nevertheless, the vast 
abundance of UCB, availability of donors, ease of proc-
urement and reliability of sample collection and lack of 
transmission of Herpesviridae viruses are advantages 
of this particular cell source.57 Furthermore, as UCB- 
MSCs are less mature than other types of adult stem 
cells, they do not elicit a strong immune rejection response 
in an allogeneic recipient, tolerating mismatches of 
HLAs. Conveniently, UCB-MSCs can be cryopreserved 
in vast quantities for later cultivation and research.57 
The doubling time of these cells is similar to that of 
BM-MSCs (i.e. every 30 hours). Overall, UCB-MSCs 
possess osteogenic, chondrogenic, adipogenic and myo- 
genic differentiation potential.57 In humans, the intrav- 
enous administration of UCB-MSCs has been success-
fully used to treat GVHD and SLE.11 Additionally, UCB- 
MSCs have been implanted to treat sciatic nerve defects 
and in post-crush and transection animal models with 
good results.9 
Recently, Wharton’s jelly (WJ) has garnered attention 
as a potential source of MSCs. The properties of WJ- 
MSCs are different from those derived from other 
sources, with WJ-MSCs exhibiting a higher proliferative 
potential independent of culture conditions.18 Never- 
theless, when cultured in the presence of serum, these 
cells produce fewer extracellular matrix components 
than BM-MSCs and AT-MSCs. In terms of clinical 
applications, WJ-MSCs have been shown to be beneficial 
and safe in the treatment of myocardial infarctions, 
positively affecting the size of the infarction and LV 
function.7 In one study, human WJ-MSCs were placed on 
a 3D scaffold in a conditioned medium obtained from a 
culture of human articular chondrocytes.18 The WJ- 
MSCs underwent chondrogenic differentiation without 
the need for growth factors, with a high accumulation of 
glycosaminoglycans and expression of cartilage-related 
genes. These observations indicate that WJ-MSCs may 
be a good option for regenerating articular cartilage.18
amniotic fluid and placenta
According to immunophenotypical analyses, the pheno- 
type of cultured cells obtained from amniotic fluid (AF) 
is similar to that of BM-MSCs.58 Cultured cells obtained 
from this source can differentiate into mesenchymal 
lineages. The expansion of AF- and amnion-derived 
MSCs is similar, with no marked differences in cell counts, 
although the latter grow at a slower pace and with 
a lower yield than BM-MSCs.19,58 AF-MSCs demonstrate 
high self-renewal capacity (>300 cell divisions) and 
a doubling time of 36 hours. Furthermore, they have 
been shown to maintain a normal karyotype even 
at late passages.58 Interestingly, AF-MSCs express 
octamer-binding transcription factor-4 (Oct-4) and 
stage-specific embryonic antigen-4 (SSEA-4) human 
embryonic stem cell markers, which is typical for 
underdifferentiated embryonic stem cells; this means 
that AF-MSCs are not primitive embryonic stem cells 
but maintain greater differentiation potential than 
most adult stem cells.19,58
In addition to common mesodermal lineages, 
AF-MSCs can also differentiate into hepatocytes and 
neurons under specific culture conditions.19 While no 
human investigations using AF-MSCs have yet been 
reported, several animal models have studied various 
clinical applications, including bladder formation using 
AF-MSCs differentiated into muscle cells, the treat-
ment of nerve injuries, blood vessel and heart valve 
formation and regeneration of the diaphragm, kidney, 
bone, lung, heart and cartilage.19,20,58 As with UCB-MSCs, 
AF-MSCs have also been successfully implanted in 
sciatic nerve defects and post-crush and transection 
animal models.9 
The basement membrane of the amnion contains 
MSCs derived from the inner cell mass of blastocysts. In 
addition to not expressing HLA class II, human amnion- 
derived MSCs possess immunosuppressive factors.58 
Other parts of the placenta, such as the decidua basalis 
and decidua parietalis, also contain MSCs; upon cultiv- 
ation, these cells exhibit similar characteristics to amnion-
derived MSCs. Placenta-derived MSCs (P-MSCs) also 
express embryonic stem cell markers such as c-Kit, 
sex determining region Y-box 2, Oct-4 and SSEA-4 
and are able to differentiate into mesenchymal as well 
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as hepatic, pancreatic and neuronal lineages.59 P-MSCs 
have been shown to improve lung function and reduce 
pulmonary fibrosis in animal models and have been 
used in the treatment of skin and ocular diseases.20,59 
Interestingly, these cells have also been used to create 
an artificial amnion within a collagen scaffold.19 Other 
clinical applications of P-MSCs in animal models incl- 
ude the formation of cardiac tissue and treatment of 
bleomycin-induced lung injuries, cartilage defects, 
inflammatory bowel disease, Duchenne muscular dys- 
trophy, ischaemic stroke, inflammation and DM.20 One 
of the main benefits of P-MSCs is that they can be 
easily obtained following delivery without the need for 
a specific procedure; they also offer distinct advantages 
in terms of proliferation and plasticity.20
mobilised peripheral blood 
Specific factors that control haematopoiesis were initially 
identified by their ability to support progenitor cells in 
culture assays. These factors have since been isolated 
and purified, allowing for the development of therapeutic 
agents, including colony-stimulating factors (CSFs).60,61 
Filgrastim, a granulocyte-CSF, is a bacterially-synthes-
ised recombinant protein that acts on neutrophils. It 
was first used in cancer patients in 1991 as an adjunct 
for ameliorating chemotherapy-induced neutropaenia. 
Filgrastim has since been approved in over 70 countries 
for mobilising peripheral blood progenitor cells for 
transplantation.60,61 Granulocyte-CSF binds selectively 
to specific cell-surface receptors, triggering the phos-
phorylation of janus kinase (JAK)1 and JAK2 protein 
tyrosine kinases and activating the Ras/mitogen-activ-
ated protein kinase pathway. A subcutaneous dose of 
filgrastim (10 µg/kg) results in a six-fold increase in 
neutrophil levels within 24–48 hours.62 Furthermore, 
filgrastim treatment reduces the neutrophil maturation 
time from five days to one day.61,62
Peripheral blood stem cells may be mobilised from 
healthy donors using granulocyte-CSFs.9 The underlying 
mechanism involves a number of adhesion molecules, 
including lymphocyte function-associated antigen 1, 
very late antigen-4, C-X-C motif chemokine receptor 4, 
c-Kit, CD44 and macrophage-1. These molecules facil- 
itate the binding of stem cells to BM and their disruption 
allows for their release into the circulation. While the 
underlying mechanism is unclear, this process is mainly 
regulated by cytokines.63,64
As a replacement for BM-MSCs, granulocyte-
CSF-mobilised peripheral blood stem cells are con-
venient and easily accessible. They are similar to BM-
MSCs in most aspects, as they can differentiate into 
mesenchymal lineages and have a strong capacity to 
adhere to plastic culture flasks.21 However, MSCs mobil-
ised from the blood using granulocyte-CSF exhibit a 
95-hour duplication time, which is longer than that of 
MSCs from other sources. Moreover, they adhere in 
a monolayer and to different scaffolds.21 Their surface 
expression profile is similar to that of BM-MSCs with 
specific MSC markers. Their capability to differentiate 
into chondral and bone lineages is lower than that of 
BM-MSCs, while their capability to differentiate into 
an adipose lineage is higher.21 As yet, no clinical trial 
on the use of these cells has been published. 
synovium and synovial fluid
In humans, cartilage and synovium originate from a 
common pool of cells during synovial joint development. 
In the treatment of musculoskeletal injuries, synovial 
MSCs are an attractive method of meniscus regen-
eration. Synovium-derived MSCs (S-MSCs) are far 
superior to cells derived from the skeletal muscle 
and AT, as determined by their in vitro expandability, 
differentiation potential and epitope profiles.65 When 
replated at a density of 50 cells/cm2, these cells retain 
their proliferative ability up to passage 10, whereas cells 
from other sources proliferate only until passage seven. 
Furthermore, these cells possess remarkable adipogenic, 
chondrogenic and osteogenic potential comparable to 
that of BM- and periosteum-derived MSCs.65 Interestingly, 
in vivo evidence suggests that the intra-articular injection 
of endogenous cells from the synovial membrane can 
contribute to the repair of partial-thickness cartilage 
defects in a mouse injury model.22 S-MSCs have also 
promoted ligament regeneration in another animal 
model.23 
Interestingly, in one study, when S-MSCs were 
implanted into the deeper aspect of an osteochondral 
defect, they differentiated into osteocytes; however, 
when they were implanted into the superficial aspect, 
the cells differentiated into chondrocytes.9 These 
observations suggest that the microenvironment may 
play an important role in the multilineage differ- 
entiation potential of MSCs.9 Furthermore, S-MSCs 
may play a role in the endogenous repair of intra-artic-
ular injuries because the number of S-MSCs in synovial 
fluid are elevated in patients with osteoarthritic knees, 
cartilage defects, meniscus damage or intra-articular 
ligament injuries.9 
endometrium
In 2004, Chan et al. hypothesised that because the 
human endometrium regenerates from the lower basalis 
layer, it might contain small populations of epithelial 
and stromal cells that exhibit clonogenicity.66 Human 
clonogenic endometrial cells exhibit the same in vitro 
properties as BM-MSCs. Human endometrial stromal 
cell cultures can differentiate in vitro, unlike other non- 
endometrial gynaecological tissues.67,68 
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There are three types of endometrial stem cells 
(EnSCs): epithelial progenitor cells, MSCs and endo-
thelial progenitor cells.68 EnSCs can be isolated from the 
menstrual blood or from endometrial biopsies without 
the need for invasive procedures.68,69 Furthermore, 
EnSCs have similar properties to those of AT- and BM- 
derived MSCs. The functional dysregulation of these 
cells may contribute to a range of pathologies, from 
endometriosis to endometrial carcinomas.24 The prolif- 
eration potential of EnSCs is 6 × 1011 cells from a single 
cell and these cells can differentiate into adipogenic, 
chondrogenic and osteogenic lineages.67,68 EnSCs have 
several clinical applications, albeit limited to preclinical 
studies. Current models include Duchenne muscular 
dystrophy, muscle repair by EnSC transplantation into 
atrophied muscle fibres, limb ischaemia and myocardial 
infarction.68
The proliferative ability of menstrual blood-derived 
MSCs (Men-MSCs) is very high and they can maintain 
a relatively stable karyotype over 40 passages. The doubling 
time of these cells is 18–36 hours, which is fast when 
compared with other types of MSCs.69–71 Men-MSCs can 
be induced into multiple lineages, including chondro-
cytes, osteoblasts, adipocytes, smooth muscle cells, myo- 
cardial cells and hepatocytes. In an animal model of 
type 1 DM, the intravenous administration of these cells 
improved hyperglycaemia.72 In another animal model, 
Men-MSCs were shown to secrete various neuro-
protective factors (e.g. vascular endothelial growth factor 
and brain-derived neurotrophic factor) which promote 
neuron survival and mitigate behavioural and histolog- 
ical changes, making them applicable for stroke treat-
ment.25 Other potential applications of Men-MSCs include 
ulcerative colitis, endometriosis, endometrial carcinomas, 
pelvic organ prolapse and cardiac failure.25
skin 
Skin-derived precursors are able to differentiate into both 
neural and mesodermal cells. These cells can be harvested 
from the human foreskin or even from skin biopsies.73 
When cultured, they differentiate into neurons, glia
and smooth muscle cells, including cells of the peripheral 
neural phenotype (consistent with cells originating from 
the neural crest), but hold limited potential for mesen- 
chymal lineage differentiation.26,73 One of the main adv- 
antages of this cell type is its proliferation rate. The skin-
derived MSCs (S-MSCs) of human newborns exhibit a 
higher proliferation rate during long-term cultures than 
human AT-MSCs and skin stromal cells.68,73 Further-
more, stem cells can be obtained from several regions 
of the skin, including the epidermis (epidermal stem 
cells), interfollicular epidermis, hair follicles, sebaceous 
glands and subcutaneous AT. Each of these stem cell 
types expresses different markers.26,27 
Although S-MSCs are able to differentiate into 
neurons, from a functional point of view, these cells 
present an immature electrophysiological profile.27
The implantation of S-MSCs into an adult mouse 
brain led to the discovery that these cells are capable 
of differentiating into astrocytes as well as insulin-
producing pancreatic cells.27 An important application 
of S-MSCs is skin regeneration after serious skin 
damage, such as that caused by burns, chronic ulcers 
and deep wounds, as well as anti-ageing therapy and 
repigmentation in vitiligo, alopaecia and melanoma 
cases. Other potential clinical applications of S-MSCs 
currently being studied include spinal cord injuries, 
regeneration of the haematopoietic lineage after 
radiotherapy, bladder reconstruction and alopecia.27 
Undifferentiated hair follicle stem cells have also been 
used in murine models of sciatic and tibial nerve tran- 
sections and crush injuries, with the animals exhib-
iting improved functional outcomes after cell admin-
istration.9
muscle
The skeletal muscle and bone share a common meso-
dermal origin and these tissues exhibit regenerative 
capacities due to the presence of endogenous muscle 
stem cells, satellite cells and skeletal stem cells.74 It is 
important to distinguish between satellite cells and 
muscle-derived MSCs (M-MSCs), as the former are 
committed to a myogenic lineage while the latter 
are satellite cell predecessors capable of multilineage 
differentiation. Other subtypes of M-MSCs include 
myoendothelial cells—which express surface markers 
of both endothelial and satellite cells—and traumatised 
M-MSCs which are rapidly adherent.74 M-MSCs differ- 
entiate into mesenchymal tissues, including osteogenic, 
myogenic and even chondrogenic lineages. The most 
important and extensively researched clinical application 
of this cell type is for use in the treatment of muscular 
dystrophy.75
Overall, M-MSCs have many clinical applications; 
for instance, upon transfection with the bone morpho-
genetic protein-4 gene, M-MSCs were able to differ-
entiate into osteoblasts and fill a critical femoral defect 
in an animal model.28 These cells have also been used 
in a similar fashion for craniofacial regeneration. In 
an animal model, the implantation of M-MSCs with 
fibrin glue directly into osteochondral defects resulted 
in persistent repair of the defect site after 24 weeks.29 
These cells, when differentiated, express type II collagen 
and proteoglycan-rich extracellular matrix. 
M-MSCs may also promote peripheral nerve reg- 
eneration, as shown in animal models of sciatic nerve 
injuries.9 Another therapeutic application of M-MSCs 
is the promotion of skeletal and cardiac muscle regen- 
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eration. Several studies have supported the possibility 
that M-MSCs can augment muscle healing following 
injury; another study found that the injection of M-MSCs 
into the infarcted region of cardiac tissue resulted in 
improved function.28 Additionally, M-MSCs can mediate 
a secondary mechanism of regeneration by promoting 
angiogenesis.28,30 Other potential applications of M-MSCs 
include vascular regeneration, the treatment of urinary 
incontinence and the repair of vaginal tissue. M-MSCs 
have also been successfully used for treating rotator cuff 
injuries.9
Legal Implications and Future 
Research 
The wide array of possibilities engendered by stem cell 
therapy have generated expectations that exceed our 
current understanding and regulations regarding their 
use. To meet these expectations, the Food and Drug 
Administration (FDA) in the USA has advocated 
further studies to assess the risks and benefits of stem 
cell therapy and develop evidence-based therapeutic 
approaches.76 Thus far, the FDA has only approved stem 
cell treatments sourced from BM aspirate concentrate.9 
While haematopoietic reconstitution using BM- or 
peripheral blood-derived MSCs is a well-known, safe 
and effective treatment, there is a lack of research 
regarding the safety and efficacy of other sources of 
MSCs. In some cases, these sources may be used with 
only minimal clinical evidence.76–78
Some of the arguments used to justify these pract-
ices include the capacity of MSCs to repair damage; the 
extremely high cost of clinical trials necessitating large 
industrial sponsors; and the assumption that stem cell 
therapies are safe, especially when derived from an auto- 
logous source.76,77 The modern clinician should under- 
stand the basis of regenerative medicine, the clinical 
options at their disposal and the potential of such therapies 
to drive medical decisions. However, they must also 
protect patients from pseudomedical treatments that 
have been widely popularised to constitute stem cell 
therapies. Most clinical options for stem cell therapy 
focus on chronic conditions because of the relatively 
slow pace of transplantable stem cell generation. In 
general, such procedures require the procurement, isol- 
ation, expansion, differentiation and implantation of a 
sufficient number of cells before a therapeutic response 
is noted.76–78
In different countries, regulations for regener-
ative medicine products allow for exceptions to long- 
established safety rules. For example, in Japan, such 
products can be marketed based on preliminary evid- 
ence and are only required to meet reduced thresholds 
for therapeutic efficacy.74 In the USA, the 21st Century 
Cures Act of 2016 saw the inception of the term 
‘regenerative advanced therapy’ for the purpose of 
expediting regulatory processes.77 Nevertheless, clinical 
trials should be performed to ensure the safe and 
effective use of therapies involving MSCs, regardless 
of cell source or clinical application. Moreover, specific 
laws should be implemented for further control over 
the use of these cells.78
In the future, once the aforementioned challenges 
have been resolved, it might be possible to replicate 
the exact function of native tissues by differentiating 
MSCs identical to the organs in need of replacement. 
Furthermore, the differentiation process might be perf- 
ormed in vivo, leading to standardised stem cell ther-
apies for various ailments. 
Conclusion 
Although BM-MSCs have been the main source of 
stem cells for many years, the inconvenience and risk 
of procuring these cells has fuelled research for alter-
native and more practical sources. As shown in this 
review, MSCs have many clinical applications, with 
an important role in almost all medical and surgical 
specialties. It is important to recognise that the thera-
peutic use of MSCs is not an unrealistic goal, as stem 
cells already offer a promising option in the treatment 
of several diseases. Nevertheless, the safety and efficacy 
of all types of MSCs, regardless of source, should be 
carefully assessed prior to their application, first in 
animal models and subsequently in clinical trials.
References
1. Choo A, Ngo AS, Ding V, Oh S, Kiang LS. Autogeneic feeders 
for the culture of undifferentiated human embryonic stem cells 
in feeder and feeder-free conditions. Methods Cell Biol 2008; 
86:15–28. doi: 10.1016/S0091-679X(08)00002-2.
2. Hiew VV, Simat SFB, Teoh PL. The advancement of biomaterials 
in regulating stem cell fate. Stem Cell Rev 2018; 14:43–57. 
doi: 10.1007/s12015-017-9764-y.
3. Lv FJ, Tuan RS, Cheung KM, Leung VY. Concise review: The 
surface markers and identity of human mesenchymal stem 
cells. Stem Cells 2014; 32:1408–19. doi: 10.1002/stem.1681. 
4. Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal 
stem cells: A new trend for cell therapy. Acta Pharmacol Sin 
2013; 34:747–54. doi: 10.1038/aps.2013.50.
5. Liras A. Future research and therapeutic applications of human 
stem cells: General, regulatory, and bioethical aspects. J Transl 
Med 2010; 8:131. doi: 10.1186/1479-5876-8-131.
6. Stanko P, Kaiserova K, Altanerova V, Altaner C. Comparison 
of human mesenchymal stem cells derived from dental pulp, 
bone marrow, adipose tissue, and umbilical cord tissue by gene 
expression. Biomed Pap Med Fac Univ Palacky Olomouc Czech 
Repub 2014; 158:373–7. doi: 10.5507/bp.2013.078.
Roberto Berebichez-Fridman and Pablo R. Montero-Olvera
Review | e275
7. Majka M, Sułkowski M, Badyra B, Musiałek P. Concise review: 
Mesenchymal stem cells in cardiovascular regeneration - Emer-
ging research directions and clinical applications. Stem Cells 
Transl Med 2017; 6:1859–67. doi: 10.1002/sctm.16-0484. 
8. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, 
Marini F, Krause D, et al. Minimal criteria for defining multi-
potent mesenchymal stromal cells: The International Society 
for Cellular Therapy position statement. Cytotherapy 2006; 
8:315–17. doi: 10.1080/14653240600855905.
9. Berebichez-Fridman R, Gómez-García R, Granados-Montiel J, 
Berebichez-Fastlicht E, Olivos-Meza A, Granados J, et al. The holy 
grail of orthopedic surgery: Mesenchymal stem cells - Their current 
uses and potential applications. Stem Cells Int 2017; 2017:2638305. 
doi: 10.1155/2017/2638305. 
10. Cheng HY, Ghetu N, Wallace CG, Wei FC, Liao SK. The impact of 
mesenchymal stem cell source on proliferation, differentiation, 
immunomodulation and therapeutic efficacy. J Stem Cell Res 
Ther 2014; 4:237. doi: 10.4172/2157-7633.1000237.
11. Cagliani J, Grande D, Molmenti EP, Miller EJ, Rilo HLR. 
Immunomodulation by mesenchymal stromal cells and their 
clinical applications. J Stem Cell Regen Biol 2017; 3:1–26. 
doi: 10.15436/2471-0598.17.022.
12. Mafi R, Hindocha S, Mafi P, Griffin M, Khan WS. Sources of 
adult mesenchymal stem cells applicable for musculoskeletal 
applications: A systematic review of the literature. Open Orthop 
J 2011; 5:242–8. doi: 10.2174/1874325001105010242.
13. Yang JA, Chung HM, Won CH, Sung JH. Potential application of 
adipose-derived stem cells and their secretory factors to skin: 
Discussion from both clinical and industrial viewpoints. Expert 
Opin Biol Ther 2010; 10:495–503. doi: 10.1517/14712591003610598. 
14. Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal 
human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc 
Natl Acad Sci U S A 2000; 97:13625–30. doi: 10.1073/pnas.240 
309797.
15. Kushnerev E, Shawcross SG, Sothirachagan S, Carley F, Brahma A, 
Yates JM, et al. Regeneration of corneal epithelium with dental 
pulp stem cells using a contact lens delivery system. Invest 
Ophthalmol Vis Sci 2016; 57:5192–9. doi: 10.1167/iovs.15-17953. 
16. Tatullo M, Codispoti B, Pacifici A, Palmieri F, Marrelli M, 
Pacifici L, et al. Potential use of human periapical cyst-mesen-
chymal stem cells (hPCy-MSCs) as a novel stem cell source for 
regenerative medicine applications. Front Cell Dev Biol 2017; 
5:103. doi: 10.3389/fcell.2017.00103.
17. Vasandan AB, Shankar SR, Prasad P, Sowmya Jahnavi V, 
Bhonde RR, Jyothi Prasanna S. Functional differences in mesen-
chymal stromal cells from human dental pulp and periodontal liga-
ment. J Cell Mol Med 2014; 18:344–54. doi: 10.1111/jcmm.12192.
18. Alves da Silva ML, Costa-Pinto AR, Martins A, Correlo VM, 
Sol P, Bhattacharya M, et al. Conditioned medium as a strategy 
for human stem cells chondrogenic differentiation. J Tissue Eng 
Regen Med 2015; 9:714–23. doi: 10.1002/term.1812.
19. Joo S, Ko IK, Atala A, Yoo JJ, Lee SJ. Amniotic fluid-derived 
stem cells in regenerative medicine research. Arch Pharm Res 
2012; 35:271–80. doi: 10.1007/s12272-012-0207-7.
20. Pipino C, Shangaris P, Resca E, Zia S, Deprest J, Sebire NJ, et al. 
Placenta as a reservoir of stem cells: An underutilized resource? 
Br Med Bull 2013; 105:43–68. doi: 10.1093/bmb/lds033.
21. Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, 
Massy M, et al. Mesenchymal stem cells derived from CD133-
positive cells in mobilized peripheral blood and cord blood: 
Proliferation, Oct4 expression, and plasticity. Stem Cells 2005; 
23:1105–12. doi: 10.1634/stemcells.2004-0330.
22. Mak J, Jablonski CL, Leonard CA, Dunn JF, Raharjo E, Matyas JR, 
et al. Intra-articular injection of synovial mesenchymal stem 
cells improves cartilage repair in a mouse injury model. Sci Rep 
2016; 6:23076. doi: 10.1038/srep23076.
23. McGonagle D, Jones E. A potential role for synovial fluid 
mesenchymal stem cells in ligament regeneration. Rheumatology 
(Oxford) 2008; 47:1114–16. doi: 10.1093/rheumatology/ken236.
24. Gargett CE, Masuda H. Adult stem cells in the endometrium. 
Mol Hum Reprod 2010; 16:818–34. doi: 10.1093/molehr/gaq061.
25. Xu Y, Zhu H, Zhao D, Tan J. Endometrial stem cells: Clinical 
application and pathological roles. Int J Clin Exp Med 2015; 
8:22039–44.
26. Toma JG, McKenzie IA, Bagli D, Miller FD. Isolation and 
characterization of multipotent skin-derived precursors from 
human skin. Stem Cells 2005; 23:727–37. doi: 10.1634/stemcells. 
2004-0134.
27. Niezgoda A, Niezgoda P, Nowowiejska L, Białecka A, Męcińska-
Jundziłł K, Adamska U, et al. Properties of skin stem cells and 
their potential clinical applications in modern dermatology. Eur 
J Dermatol 2017; 27:227–36. doi: 10.1684/ejd.2017.2988.
28. Jackson WM, Nesti LJ, Tuan RS. Potential therapeutic applic- 
ations of muscle-derived mesenchymal stem and progenitor 
cells. Expert Opin Biol Ther 2010; 10:505–17. doi: 10.1517/147 
12591003610606.
29. Gates CB, Karthikeyan T, Fu F, Huard J. Regenerative medicine 
for the musculoskeletal system based on muscle-derived stem 
cells. J Am Acad Orthop Surg 2008; 16:68–76.
30. Hass R, Kasper C, Böhm S, Jacobs R. Different populations and 
sources of human mesenchymal stem cells (MSC): A comparison 
of adult and neonatal tissue-derived MSC. Cell Commun Signal 
2011; 9:12. doi: 10.1186/1478-811X-9-12.
31. Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol 
1976; 47:327–59.
32. Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow 
osteogenic stem cells: In vitro cultivation and transplantation 
in diffusion chambers. Cell Tissue Kinet 1987; 20:263–72.
33. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative 
analysis of mesenchymal stem cells from bone marrow, umbil-
ical cord blood, or adipose tissue. Stem Cells 2006; 24:1294–301. 
doi: 10.1634/stemcells.2005-0342.
34. Penn MS, Swaminath D. Novel role of bone marrow stem cells 
in systemic disease. Circ Res 2015; 117:119–20. doi: 10.1161/
CIRCRESAHA.117.306852.
35. Jackson L, Jones DR, Scotting P, Sottile V. Adult mesenchymal 
stem cells: Differentiation potential and therapeutic applications. 
J Postgrad Med 2007; 53:121–7. doi: 10.4103/0022-3859.32215.
36. Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, 
Bartunek J, et al. Impact of intracoronary cell therapy on left 
ventricular function in the setting of acute myocardial infarc-
tion: A collaborative systematic review and meta-analysis of 
controlled clinical trials. J Am Coll Cardiol 2007; 50:1761–7. 
doi: 10.1016/j.jacc.2007.07.041.
37. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, 
De Simone G, et al. Heart disease and stroke statistics: 2010 
update - A report from the American Heart Association. Circul- 
ation 2010; 121:e46–215. doi: 10.1161/CIRCULATIONAHA. 
109.192667.
38. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 
2008; 451:937–42. doi: 10.1038/nature06800.
39. Nguyen PK, Lan F, Wang Y, Wu JC. Imaging: Guiding the 
clinical translation of cardiac stem cell therapy. Circ Res 2011; 
109:962–79. doi: 10.1161/CIRCRESAHA.111.242909.
40. Forest VF, Tirouvanziam AM, Perigaud C, Fernandes S, Fusellier MS, 
Desfontis JC, et al. Cell distribution after intracoronary 
bone marrow stem cell delivery in damaged and undamaged 
myocardium: Implications for clinical trials. Stem Cell Res Ther 
2010; 1:4. doi: 10.1186/scrt4.
Sources and Clinical Applications of Mesenchymal Stem Cells 
State-of-the-art review
e276 | SQU Medical Journal, August 2018, Volume 18, Issue 3
41. Poulsen SH, Jensen SE, Egstrup K. Longitudinal changes and 
prognostic implications of left ventricular diastolic function in 
first acute myocardial infarction. Am Heart J 1999; 137:910–18. 
doi: 10.1016/S0002-8703(99)70416-3.
42. Schaefer A, Zwadlo C, Fuchs M, Meyer GP, Lippolt P, Wollert KC, 
et al. Long-term effects of intracoronary bone marrow cell 
transfer on diastolic function in patients after acute myocardial 
infarction: 5-year results from the randomized-controlled 
BOOST trial - An echocardiographic study. Eur J Echocardiogr 
2010; 11:165–71. doi: 10.1093/ejechocard/jep191.
43. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, 
Hosing C, et al. Hyperacute GVHD: Risk factors, outcomes, 
and clinical implications. Blood 2006; 109:2751–8. doi: 10.1182/
blood-2006-07-034348.
44. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, 
Uzunel M, et al. Treatment of severe acute graft-versus-host 
disease with third party haploidentical mesenchymal stem cells. 
Lancet 2004; 363:1439–41. doi: 10.1016/S0140-6736(04)16104-7.
45. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, 
et al. Bone marrow mesenchymal stem cells inhibit the response 
of naive and memory antigen-specific T cells to their cognate 
peptide. Blood 2003; 101:3722–9. doi: 10.1182/blood-2002-07-2104.
46. Wang LT, Ting CH, Yen ML, Liu KJ, Sytwu HK, Wu KK, et al. 
Human mesenchymal stem cells (MSCs) for treatment towards 
immune- and inflammation-mediated diseases: Review of current 
clinical trials. J Biomed Sci 2016; 23:76. doi: 10.1186/s12929-
016-0289-5.
47. Houlihan DD, Hopkins LJ, Suresh SX, Armstrong MJ, Newsome PN. 
Autologous bone marrow mesenchymal stem cell transplantation 
in liver failure patients caused by hepatitis B: Short-term and long- 
term outcomes. Hepatology 2011; 54:1891–2. doi: 10.1002/hep.24722.
48. Choudhery MS, Badowski M, Muise A, Pierce J, Harris DT. 
Donor age negatively impacts adipose tissue-derived mesen-
chymal stem cell expansion and differentiation. J Transl Med 
2014; 12:8. doi: 10.1186/1479-5876-12-8.
49. Inatani H, Yamamoto N, Hayashi K, Kimura H, Takeuchi A, 
Miwa S, et al. Do mesenchymal stem cells derived from atypical 
lipomatous tumors have greater differentiation potency than 
cells from normal adipose tissues? Clin Orthop Relat Res 2017; 
475:1693–701. doi: 10.1007/s11999-017-5259-z.
50. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, 
Campbell N, et al. Induction of solid tumor differentiation by 
the peroxisome proliferator-activated receptor-gamma ligand 
troglitazone in patients with liposarcoma. Proc Natl Acad Sci 
U S A 1999; 96:3951–6. doi: 10.1073/pnas.96.7.3951.
51. Artigas N, Gámez B, Cubillos-Rojas M, Sánchez-de Diego C, 
Valer JA, Pons G, et al. p53 inhibits SP7/osterix activity in 
the transcriptional program of osteoblast differentiation. Cell 
Death Differ 2017; 24:2022–31. doi: 10.1038/cdd.2017.113.
52. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, 
cancer, and cancer stem cells. Nature 2001; 414:105–11. 
doi: 10.1038/35102167.
53. Sanz AR, Carrión ES, Chaparro AP. Mesenchymal stem cells 
from the oral cavity and their potential value in tissue engineering. 
Periodontol 2000 2015; 67:251–67. doi: 10.1111/prd.12070.
54. Ohkoshi S, Hara H, Hirono H, Watanabe K, Hasegawa K. Regen- 
erative medicine using dental pulp stem cells for liver diseases. 
World J Gastrointest Pharmacol Ther 2017; 8:1–6. doi: 10.4292/
wjgpt.v8.i1.1.
55. Ishkitiev N, Yaegaki K, Calenic B, Nakahara T, Ishikawa H, 
Mitiev V, et al. Deciduous and permanent dental pulp mesen-
chymal cells acquire hepatic morphologic and functional features 
in vitro. J Endod 2010; 36:469–74. doi: 10.1016/j.joen.2009.12.022.
56. Lei M, Li K, Li B, Gao LN, Chen FM, Jin Y. Mesenchymal stem 
cell characteristics of dental pulp and periodontal ligament 
stem cells after in vivo transplantation. Biomaterials 2014; 
35:6332–43. doi: 10.1016/j.biomaterials.2014.04.071.
57. Gang EJ, Hong SH, Jeong JA, Hwang SH, Kim SW, Yang IH, 
et al. In vitro mesengenic potential of human umbilical cord 
blood-derived mesenchymal stem cells. Biochem Biophys Res 
Commun 2004; 321:102–8. doi: 10.1016/j.bbrc.2004.06.111.
58. Koike C, Zhou K, Takeda Y, Fathy M, Okabe M, Yoshida T, et al. 
Characterization of amniotic stem cells. Cell Reprogram 2014; 
16:298–305. doi: 10.1089/cell.2013.0090.
59. In’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, 
de Groot-Swings GM, Claas FH, Fibbe WE, et al. Isolation 
of mesenchymal stem cells of fetal or maternal origin from 
human placenta. Stem Cells 2004; 22:1338–45. doi: 10.1634/
stemcells.2004-0058.
60. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor 
and its receptor. Blood 1991; 78:2791–808.
61. Chao NJ, Schriber JR, Grimes K, Long GD, Negrin RS, 
Raimondi CM, et al. Granulocyte colony-stimulating factor 
“mobilized” peripheral blood progenitor cells accelerate granu-
locyte and platelet recovery after high-dose chemotherapy. 
Blood 1993; 81:2031–5. 
62. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. 
Filgrastim (r-metHuG-CSF): The first 10 years. Blood 1996; 
88:1907–29. 
63. Craddock CF, Nakamoto B, Andrews RG, Priestley GV, 
Papayannopoulou T. Antibodies to VLA4 integrin mobilize 
long-term repopulating cells and augment cytokine-induced 
mobilization in primates and mice. Blood 1997; 90:4779–88. 
64. Kikuta T, Shimazaki C, Ashihara E, Sudo Y, Hirai H, Sumikuma T, 
et al. Mobilization of hematopoietic primitive and committed 
progenitor cells into blood in mice by anti-vascular adhesion 
molecule-1 antibody alone or in combination with granulocyte 
colony-stimulating factor. Exp Hematol 2000; 28:311–17. 
doi: 10.1016/S0301-472X(99)00151-4.
65. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. Comparison of 
human stem cells derived from various mesenchymal tissues: 
Superiority of synovium as a cell source. Arthritis Rheum 2005; 
52:2521–9. doi: 10.1002/art.21212.
66. Chan RW, Schwab KE, Gargett CE. Clonogenicity of human 
endometrial epithelial and stromal cells. Biol Reprod 2004; 
70:1738–50. doi: 10.1095/biolreprod.103.024109.
67. Wolff EF, Wolff AB, Hongling Du, Taylor HS. Demonstration of 
multipotent stem cells in the adult human endometrium by in 
vitro chondrogenesis. Reprod Sci 2007; 14:524–33. doi: 10.1177/ 
1933719107306896.
68. Verdi J, Tan A, Shoae-Hassani A, Seifalian AM. Endometrial 
stem cells in regenerative medicine. J Biol Eng 2014; 8:20. 
doi: 10.1186/1754-1611-8-20.
69. Gargett CE. Uterine stem cells: What is the evidence? Hum 
Reprod Update 2007; 13:87–101. doi: 10.1093/humupd/dml045.
70. Schüring AN, Schulte N, Kelsch R, Röpke A, Kiesel L, Götte M. 
Characterization of endometrial mesenchymal stem-like cells 
obtained by endometrial biopsy during routine diagnostics. Fertil 
Steril 2011; 95:423–6. doi: 10.1016/j.fertnstert.2010.08.035.
71. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, 
Mosca JD, et al. Multilineage potential of adult human mesen-
chymal stem cells. Science 1999; 284:143–7. doi: 10.1126/science. 
284.5411.143.
72. Wu X, Luo Y, Chen J, Pan R, Xiang B, Du X, et al. Transplant-
ation of human menstrual blood progenitor cells improves 
hyperglycemia by promoting endogenous progenitor differen-
tiation in type 1 diabetic mice. Stem Cells Dev 2014; 23:1245–
57. doi: 10.1089/scd.2013.0390.
73. Al-Nbaheen M, Vishnubalaji R, Ali D, Bouslimi A, Al-Jassir F, 
Megges M, et al. Human stromal (mesenchymal) stem cells from 
bone marrow, adipose tissue and skin exhibit differences in 
molecular phenotype and differentiation potential. Stem Cell 
Rev 2013; 9:32–43. doi: 10.1007/s12015-012-9365-8.
Roberto Berebichez-Fridman and Pablo R. Montero-Olvera
Review | e277
74. Abou-Khalil R, Yang F, Lieu S, Julien A, Perry J, Pereira C, 
et al. Role of muscle stem cells during skeletal regeneration. 
Stem Cells 2015; 33:1501–11. doi: 10.1002/stem.1945.
75. Peng H, Huard J. Muscle-derived stem cells for musculoskeletal 
tissue regeneration and repair. Transpl Immunol 2004; 12:311–19. 
doi: 10.1016/j.trim.2003.12.009.
76. Marks PW, Witten CM, Califf RM. Clarifying stem-cell 
therapy’s benefits and risks. N Engl J Med 2017; 376:1007–9. 
doi: 10.1056/NEJMp1613723.
77. Daley GQ. Polar extremes in the clinical use of stem cells. N 
Engl J Med 2017; 376:1075–7. doi: 10.1056/NEJMe1701379.
78. Marks P, Gottlieb S. Balancing safety and innovation for cell-
based regenerative medicine. N Engl J Med 2018; 378:954–9. 
doi: 10.1056/NEJMsr1715626.
